| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/03/2001 | US6210674 GreA from Staphylococcus aureus |
| 04/03/2001 | US6210394 Surgical irrigation solution and method for inhibition of pain and inflammation |
| 04/03/2001 | US6210343 Use of misoprostol or/and misoprostol acid for diagnosis of vascular damage in a subject with erectile dysfunction |
| 04/03/2001 | CA2224795C Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders |
| 04/03/2001 | CA2211120C Lineage-directed induction of human mesenchymal stem cell differentiation |
| 04/01/2001 | CA2321593A1 .alpha.-sulfonylamino hydroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders |
| 03/30/2001 | WO2003044525A1 Targeting cells having mad2 mutation for treatment and/or prevention of disease |
| 03/30/2001 | WO2003042411A2 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease |
| 03/30/2001 | WO2002090588A1 Interfering with telomere maintenance in treatment of diseases |
| 03/30/2001 | CA2384139A1 Interfering with telomere maintenance in treatment of diseases |
| 03/30/2001 | CA2321379A1 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors |
| 03/30/2001 | CA2321378A1 Combination effective for the treatment of impotence |
| 03/29/2001 | WO2001022092A2 Method to identify compounds which modulate fra-1 expression fils |
| 03/29/2001 | WO2001022090A1 Method for identifying compounds useful in the therapy of bone disorders |
| 03/29/2001 | WO2001021799A1 Traf4 associated cell cycle proteins, compositions and methods of use |
| 03/29/2001 | WO2001021771A2 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents |
| 03/29/2001 | WO2001021765A2 Method for the selective protection of proliferating normal cells and the selective eradication of tumor cells having an inactive p53 pathway |
| 03/29/2001 | WO2001021651A2 Novel human protease inhibitor-like proteins and polynucleotides encoding the same |
| 03/29/2001 | WO2001021642A1 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use |
| 03/29/2001 | WO2001021614A1 5-aminoalkyl and 5-aminocarbonyl substituted indoles |
| 03/29/2001 | WO2001021602A1 Oxa- and thiazole derivatives useful as antidiabetic and antiobesity agents |
| 03/29/2001 | WO2001021574A1 Systems and methods for opening obstructed biological conduits |
| 03/29/2001 | WO2001021259A2 Use and compositions for treating platelet-related disorders using anagrelide |
| 03/29/2001 | WO2001021215A1 Cell based assay |
| 03/29/2001 | WO2001021213A2 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | WO2001021210A1 Anionic amino acid based surfactants to enhance antimicrobial effectiveness of topical pharmaceutical compositions |
| 03/29/2001 | WO2001021202A2 Treatment of chronic inflammatory disease by inhibiting sub-groups of activated t-cells |
| 03/29/2001 | WO2001021196A1 Method and compositions for inhibiting adhesion formation |
| 03/29/2001 | WO2001021194A2 Method for the therapeutic management of endometriosis and fallopian tube obstruction |
| 03/29/2001 | WO2001021193A1 Hybrid peptides modulate the immune response |
| 03/29/2001 | WO2001021190A1 Treatment for narcolepsy |
| 03/29/2001 | WO2001021171A1 Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores |
| 03/29/2001 | WO2001021170A1 Systems for delivering anti-infective compositions from frangible ampules to treat disordered tissue such as cold sores |
| 03/29/2001 | WO2001021163A2 Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents |
| 03/29/2001 | WO2001021158A2 Medicament combinations of nifedipine and cerivastatin |
| 03/29/2001 | WO2001021154A2 Surface modified particulate compositions of biologically active substances |
| 03/29/2001 | WO2001021008A2 Method for increasing pet activity |
| 03/29/2001 | WO2001020981A2 Anti-infective compositions for treating disordered tissue such as cold sores |
| 03/29/2001 | WO2001007067A3 Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 03/29/2001 | WO2001002557A8 Neurotrophic factor receptor |
| 03/29/2001 | WO2001000612A3 Respiratory syncytial virus replication inhibitors |
| 03/29/2001 | WO2000061182A3 Methods and compositions for the treatment and prevention of lung disease involving a selective rar-alpha agonist |
| 03/29/2001 | WO2000061078A3 Sunscreen agents containing hydroxycarboxylic acid alkyl- and/or -alkenyloligoglycoside esters |
| 03/29/2001 | WO2000032775A9 Pth1r and pth3r receptors |
| 03/29/2001 | WO2000021515A9 Intranasal codeine for the rapid suppression of cough and rapid relief of pain |
| 03/29/2001 | US20010000075 Neurotactin and uses therefor |
| 03/29/2001 | DE19944803A1 Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln Combination of dihydropyridine and HMG-CoA reductase inhibitors and their use in medicaments |
| 03/29/2001 | CA2847143A1 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | CA2805979A1 Inhibition of secretiion from non-neuronal cells |
| 03/29/2001 | CA2386767A1 Novel human protease inhibitor-like proteins and polynucleotides encoding the same |
| 03/29/2001 | CA2385879A1 Traf4 associated cell cycle proteins, compositions and methods of use |
| 03/29/2001 | CA2385488A1 Systems and methods for opening obstructed biological conduits |
| 03/29/2001 | CA2385445A1 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use |
| 03/29/2001 | CA2385424A1 Method for the selective protection of proliferating normal cells and the selective eradication of tumor cells having an inactive p53 pathway |
| 03/29/2001 | CA2385377A1 Method to identify compounds useful in the therapy of bone disorders |
| 03/29/2001 | CA2385257A1 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents |
| 03/29/2001 | CA2384928A1 Method for identifying compounds useful in the therapy of bone disorders |
| 03/29/2001 | CA2384829A1 Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores |
| 03/29/2001 | CA2384812A1 Method and compositions for inhibiting adhesion formation |
| 03/29/2001 | CA2384797A1 Medicament combinations |
| 03/29/2001 | CA2383629A1 Hybrid peptides modulate the immune response |
| 03/29/2001 | CA2383591A1 Cell based assay |
| 03/29/2001 | CA2383589A1 Anionic amino acid based surfactants to enhance antimicrobial effectiveness of topical pharmaceutical compositions |
| 03/29/2001 | CA2383510A1 Method for the therapeutic management of extrauterine proliferation of endometreial tissue, chronic pelvic pain and fallopian tube obstruction |
| 03/29/2001 | CA2383470A1 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | CA2383462A1 Therapeutic methods and compounds |
| 03/29/2001 | CA2382547A1 Methods and compositions for treating platelet-related disosders |
| 03/28/2001 | EP1087230A1 Method for identifying compounds useful in the therapy of bone disorders |
| 03/28/2001 | EP1086705A1 Vegf activity inhibitors |
| 03/28/2001 | EP1086702A2 Method for reduction of headache pain |
| 03/28/2001 | EP1086701A2 Simethicone containing laxative composition |
| 03/28/2001 | EP1086697A2 New combination of formoterol and budesonide |
| 03/28/2001 | EP1086692A2 Estrogen agonists and antagonists for multiple indications |
| 03/28/2001 | EP1086249A2 Diagnostic method based on quantification of extramitochondrial dna |
| 03/28/2001 | EP1086238A1 Human mp52 gene promoter and method for exploring useful substance by using the same |
| 03/28/2001 | EP1086234A1 New human carboxypeptidase inhibitor |
| 03/28/2001 | EP1086232A1 A vaccine-induced hepatitis b viral strain and uses thereof |
| 03/28/2001 | EP1086225A2 Human tumour-derived polypeptide hormone phosphatonin |
| 03/28/2001 | EP1086222A2 Cell cycle regulation proteins |
| 03/28/2001 | EP1086219A2 Proteins regulating gene expression |
| 03/28/2001 | EP1086207A1 Novel methods and interferon deficient substrates for the propagation of viruses |
| 03/28/2001 | EP1086137A1 Composition and method for modulating dendritic cell-t cell interaction |
| 03/28/2001 | EP1086136A1 Monoclonal antibodies specific for guanidino group-derived advanced glycosylation endproducts in biological samples |
| 03/28/2001 | EP1086125A1 Respiratory nitrate reductase alpha subunit |
| 03/28/2001 | EP1086099A1 Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds |
| 03/28/2001 | EP1086064A2 Directed combinatorial compound library and high throughput assays for screening same |
| 03/28/2001 | EP1086063A1 Novel potassium channel drugs and their uses |
| 03/28/2001 | EP1085904A1 Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals |
| 03/28/2001 | EP1085903A1 Egg surface proteins and methods for use for modulating fertility |
| 03/28/2001 | EP1085902A2 Therapeutic compositions that produce an immune response by altering the antigen |
| 03/28/2001 | EP1085897A1 Acrp30r1l, a homolog of acrp30 (30 kd adipocyte complement-related protein) |
| 03/28/2001 | EP1085894A1 Beta 3-adrenergic receptor agonists |
| 03/28/2001 | EP1085890A1 Novel sodium channel drugs and uses |
| 03/28/2001 | EP1085889A2 Novel therapeutic agents that modulate endothelin receptors |
| 03/28/2001 | EP1085887A2 Novel angiotensin receptor modulators and their uses |
| 03/28/2001 | EP1085880A2 Use of alkylating compounds for inhibiting proliferation of arterial smooth muscle cells |
| 03/28/2001 | EP1085879A2 Multibinding agents that modulate the 5-ht transporter |
| 03/28/2001 | EP1085878A2 Use of aminosterol derivatives as chloride ionophores |
| 03/28/2001 | EP1085877A1 Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma |
| 03/28/2001 | EP1085870A2 Multivalent agonists, partial agonists and antagonists of the gaba receptors |